Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a Single-arm, Prospective, Open-label Pilot Study to Evaluate the Safety and Efficacy of Dual Costimulation Blockade With VIB4920 and Belatacept for Prophylaxis of Allograft Rejection in Adults Receiving a Kidney Transplant

NCT04046549 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT04046549
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04046549 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a Single-arm, Prospective, Open-label Pilot Study to Evaluate the Safety and Efficacy of Dual Costimulation Blockade With VIB4920 and Belatacept for Prophylaxis of Allograft Rejection in Adults Receiving a Kidney Transplant
Lead sponsor
Amgen
Phase
Phase 2
Overall status
Completed
Start date
October 30, 2019
Completion date
March 22, 2023
Enrollment
25 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

allografts, kidney transplantation, rejection; transplant, kidney, transplant rejection